Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer
    Meeting Abstract

    Niazi, T.; McBride, S. M.; Williams, S.; Davis, I. D.; Stockler, M. R.; Martin, A. J.; Chung, H. T.; Roncolato, F.; Ebacher, A.; Khoo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer
    Meeting Abstract

    Nagar, H.; Ballman, K. V.; Tagawa, S. T.; Tan, A.; Faltas, B. M.; Sheybani, A.; Baghaie, S.; Schwartz, L. H.; Kozono, D. E.; Bogart, J. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin (BCG) for patients with BCG-exposed, high-grade, non-muscle–invasive bladder cancer
    Meeting Abstract

    Gaffney, C.; Dsouza, N.; Hernandez, C.; McCarter, M.; Moran, P.; Stasi, K.; Worth, K.; Dalbagni, G.; Donahue, T. F.; Donat, S. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio)
    Meeting Abstract

    Hahn, A. W.; Slack Tidwell, R.; Thoman, W.; Abdulla, A.; Koutroumpakis, E.; Aparicio, A.; Subudhi, S. K.; Siddiqui, B. A.; Pilié, P. G.; Zurita, A. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Results from phase 3 study of (89)Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON)
    Meeting Abstract

    Shuch, B. M.; Pantuck, A. J.; Bernhard, J. C.; Morris, M. A.; Master, V. A.; Scott, A. M.; Van Praet, C.; Bailly, C.; Aksoy, T.; Merkx, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Bryce, A. H.; Karp, D. D.; Tagawa, S. T.; Nordquist, L. T.; Rathkopf, D. E.; Adra, N.; Dorff, T. B.; Baeck, J.; O'Donnell, J. F.; Ames, T. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial
    Meeting Abstract

    Necchi, A.; Roumiguié, M.; Esen, A. A.; Lebret, T.; De Wit, R.; Shore, N. D.; Bajorin, D. F.; Krieger, L. E. M.; Kandori, S.; Uchio, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and immunogenomic outcomes of consolidative cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint blockade
    Meeting Abstract

    Reese, S. W.; Jiang, H.; Kuo, F.; Wu, C. Y.; Vuong, L.; Mascareno, E.; Oparanozie, A.; Motzer, R. J.; Voss, M. H.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save